free encyclopedia jump navigation jump search ovarian cancer ovarian tumour micrograph mucinous ovarian carcinoma stain
oncology symptom early vague later bloat pelvic pain abdominal swell loss appetite usual onset usual age diagnosis year old type carcinoma germ cell tumor sex cord stromal tumor risk factor children hormone therapy menopause fertility medication obesity genetics diagnostic method tissue biopsy treatment surgery radiation therapy chemotherapy survival rate frequency death
ovarian cancer cancer form ovary result abnormal cell ability invade spread part body process begin vague symptom symptom become noticeable cancer progress symptom include bloat pelvic pain abdominal swell loss appetite common area cancer spread include line abdomen lymph node lung liver
risk ovarian cancer increase women ovulate lifetime
include children begin ovulation younger age reach menopause older age risk factor include hormone therapy menopause fertility medication obesity factor decrease risk include hormonal birth control tubal ligation breast feed case relate inherit genetic risk women mutation gene chance develop disease carcinoma common type ovarian cancer comprise case main subtype ovarian carcinoma high-grade serous carcinoma hgsc common tumor believe start cell cover ovary form fallopian tube common type ovarian cancer include germ cell sex cord stromal diagnosis ovarian cancer confirm biopsy tissue usually remove surgery
screen recommend women average risk evidence support reduction death high rate false positive test lead surgery accompany risk high risk ovary remove preventive measure caught treate early stage ovarian cancer curable treatment usually include combination surgery radiation therapy chemotherapy outcome depend extent disease subtype cancer present medical condition overal five-year survival rate united states outcome worse develop world
new case occure approximately women present women result death worldwide women seventh-most common cancer eighth-most common cause death cancer typical age diagnosis death ovarian cancer common north america europe africa asia content
sign symptom early symptom later symptom children risk factor genetics environmental factor protective factor diagnosis examination pathology screen prevention management surgery radiation therapy therapy follow-up care care factor survival rate rate epidemiology united states united kingdom older women pregnancy animal research screen research pharmacology radiation clinical trial reference further read external link
sign symptom early symptom site ovarian cancer
early sign symptom ovarian cancer absent subtle
case symptom exist month recognize diagnose symptom misdiagnose irritable bowel syndrome early stage ovarian cancer tend painless
symptom vary base subtype low malignant potential known borderline cause increase ca125 level identifiable ultrasound
typical symptom lmp tumor include abdominal distension pelvic pain
particularly large mass tend benign borderline
typical symptom ovarian cancer include bloat abdominal pelvic pain discomfort back pain irregular menstruation postmenopausal vaginal bleed pain bleed sexual intercourse loss appetite fatigue indigestion heartburn constipation nausea feel full possibly urinary symptom frequent urination urgent urination later symptom
grow mass cause pain ovarian torsion develop
symptom cause mass press abdominopelvic organ metastase symptom start occur severely usual especially significant history symptom ovarian cancer consider cause sister mary joseph nodule rarely cause grow teratoma syndrome peritoneal experience abnormal vaginal bleed menopause case
common symptom include abdominal pain adnexal mass children
adolescent children ovarian tumor symptom include severe abdominal pain irritation peritoneum bleed symptom sex produce hormone affect development secondary sex characteristics
sex tumor prepubertal children manifest early puberty abdominal pain distension common
adolescent sex experience
cancer become advance cause accumulation fluid abdomen
malignancy diagnose time cause ascite typically diagnose shortly thereafter advance cancer cause abdominal mass lymph node mass pleural effusion risk factor
ovarian cancer relate amount time spent
children risk factor ovarian cancer likely ovulation suppress pregnancy
ovulation cell constantly stimulate divide cycle continue
therefore people borne children twice risk ovarian cancer
longer period ovulation cause early menstruation late menopause risk factor obesity hormone replacement therapy raise risk
risk develop ovarian cancer women menstrual cycle menstrual cycle breast feed take oral contraceptive multiple pregnancy pregnancy early age
risk develop ovarian cancer reduce women tubal ligation colloquially known tube ty ovary remove hysterectomy operation uterus sometime cervix remove age risk factor
use fertility medication contribute borderline ovarian tumor formation link dispute difficult study fertility drug associate higher risk borderline treate infertility remain higher risk epithelial ovarian cancer successfully treate infertility subsequently give birth higher risk
due shed precancerous cell pregnancy cause remain unclear risk factor instead infertility treatment
condition ovary syndrome endometriosis associate ovarian cancer link completely confirm hormone replacement therapy hrt likely increase risk ovarian cancer
association confirm large-scale study notable study women study support link
hrt combine estrogen progesterone increase contemporaneous risk use year risk return normal cessation therapy hrt progestin increase risk endometrioid serous lower risk tumor
higher dose increase risk risk factor ovarian cancer pain menstruation
associate clear-cel endometrioid subtype low-grade stage tumor grade lower mortality
menopause obesity increase person risk ovarian cancer risk present menopause
risk relevant obese use hrt
similar association ovarian cancer appear taller people genetics further information breast ovarian cancer syndrome people ovarian breast cancer pedigree chart family
family history ovarian cancer risk factor ovarian cancer
people hereditary nonpolyposis colon cancer lynch syndrome brca-1 genetic abnormality increase risk
major genetic risk factor ovarian cancer mutation brca1 dna mismatch repair gene present ovarian cancer case
allele need mutate place person high risk
gene inherit maternal paternal line variable penetrance mutation gene usually associate increase risk breast cancer carry substantial lifetime risk ovarian cancer risk peak person
lowest risk cite highest mutation brca1 lifetime risk develop ovarian cancer mutation brca2 risky brca1 lifetime risk lowest risk cite highest risk cite average brca-associate cancer develop year sporadic counterpart people inherit mutation copy gene need mutation start process carcinogenesis people normal gene need acquire mutation
united states women first-degree relative ovarian cancer eventually get ovarian cancer place affect family member triple risk women unaffect family member
women relative ovarian cancer eventually get ovarian cancer general ovarian cancer case genetic cause mutation associate high-grade serous epithelial ovarian cancer
strong family history endometrial cancer colon cancer gastrointestinal cancer indicate presence syndrome known hereditary colorectal cancer known lynch syndrome confer higher risk develop number cancer ovarian cancer
lynch syndrome cause mutation mismatch repair gene mlh1 mlh6 risk ovarian cancer individual lynch syndrome percent people icelandic descent european jewish jewish descent hungarian descent higher risk epithelial ovarian cancer receptor beta gene seem key pathogenesis response therapy gene associate ovarian cancer brip1 msh6 cdh1 chek2 associate ovarian cancer
rare genetic disorder associate specific subtype ovarian cancer
syndrome rare genetic disorder predispose people sex cord tumour annular tubule ollier disease syndrome associate cell children associate tumor
associate basal cell carcinoma syndrome environmental factor
nation exception japan high rate epithelial ovarian cancer due diet country
caucasian 3040 higher risk ovarian cancer compare black hispanic people likely due socioeconomic factor white women tend children different rate gynecologic surgery affect risk ovarian cancer
cohort study found correlation dairy consumption ovarian cancer case-control study show correlation
mix evidence effect red meat process meat ovarian cancer
evidence suggest talc pesticide herbicide increase risk ovarian cancer american cancer society note study able accurately link single chemical environment human diet directly mutation cause ovarian cancer
alcohol consumption appear relate ovarian cancer factor investigate smoke low level vitamin blood presence inclusion ovarian cyst infection human papilloma virus cause case cervical cancer disproven risk factor ovarian cancer carcinogenicity perineal talc controversial act irritant travel reproductive tract ovary study show use perineal talc increase risk ovarian cancer use talc create greater risk use talc elsewhere body unrelate ovarian cancer sit regularly prolong period associate higher mortality epithelial ovarian cancer
risk negate regular exercise lower
increase age risk factor epithelial ovarian cancer mutation cell accumulate eventually cause cancer
slightly lower risk
smoke tobacco associate higher risk ovarian cancer smoke cessation risk eventually return normal
diet high animal fat associate ovarian cancer connection unclear
diet seem play small role ovarian cancer risk higher level c-reactive protein associate higher risk develop ovarian cancer protective factor
suppression ovulation otherwise cause damage ovarian epithelium consequently inflammation generally protective
effect achieve children take combine oral contraceptive breast feed protective factor longer period breastfeed correlate larger decrease risk ovarian cancer birth decrease risk ovarian cancer effect seen birth
combine oral contraceptive reduce risk ovarian cancer protective effect combine oral contraceptive last year discontinue regular use aspirin paracetamol associate lower risk ovarian cancer nsaids seem similar protective effect
ligation protective carcinogen unable reach ovary fimbriae vagina uterus fallopian tube ligation protective women brca1 mutation brca2 mutation reduce risk removal fallopian tube ovary bilateral dramatically reduce risk ovarian cancer breast cancer well topic research link hysterectomy lower ovarian cancer risk controversial
reason hysterectomy protective elucidate
diet include large amount carotene vitamin low amount fatspecifically diet non-starchy vegetable eg broccoly onionsmay protective research ongo area higher caffeine intake consumption cup tea day associate lower ovarian cancer risk smoke tobacco protective sex pathophysiology mutation found ovarian cancer subtype gene mutate mutation type prevalence amplification point mutation clear cell deletion point mutation low-grade nonsense mutation high-grade brca2 mutation high-grade amplification amplification high-grade serous deletion clear cell mutation somatic dynlrb1 mutation amplificationoverexpression low-grade serous fm csf-1 point mutation adult cell amplification amplification amplification low-grade serous amplification point mutation amplification point mutation amplification deletion point mutation high-grade serous amplification point mutation low-grade pik3c3 pi3k3 amplification clear cell clear cell deletion clear cell deletion point mutation
tp53 high-grade serous
ri mutation
ovarian cancer form error normal ovarian cell growth occur
usually cell grow old get damage die new cell take place
cancer start new cell form old damage cell die
buildup extra cell form mass tissue call growth tumor
abnormal cancer cell genetic abnormality cause grow excessively ovary release egg egg follicle burst open become corpus
structure need repair divide cell ovary continuous ovulation long time mean repair ovary divide cell acquire mutation division
overal common gene mutation ovarian cancer occur brca1
type ovarian cancer tend aggressive tend instability gene oncogene notably kra tumor notably common mutation type cancer kra pten type cancer aggressive type different gene mutate low-grade cancer tend mutation kra cancer grade develop low malignant potential tend mutation type cancer tend develop precursor lesion type cancer develop serous tubal intraepithelial carcinoma cancer brca mutation inevitably mutation indicate removal functional gene important cancer develop
high-grade serous cancer homologous recombination dna repair dysfunctional notch foxm1 pathway
alway mutation
mutation high-grade serous carcinoma hard characterize high degree genomic instability
essential homologous recombination dna repair germline mutation gene found people ovarian cancer common mutation brca1 frameshift mutation originate small found population ashkenazy jew
rare mucinous carcinoma mutation kra amplification known overal ovarian cancer mutation
carcinoma develop tubal intraepithelial carcinoma develop spontaneously ovarian tissue
carcinoma develop cortical inclusion cyst group epithelial ovarian cell stroma diagnosis examination large ovarian cancer seen ct micrograph carcinoma type ovarian cancer diagnose peritoneal fluid
diagnosis ovarian cancer start physical examination pelvic examination blood test ca-125 sometime marker ultrasound sometime rectovaginal examination use help plan surgery diagnosis confirm surgery inspect abdominal cavity take biopsy tissue sample microscopic analysis look cancer cell abdominal fluid
help determine ovarian mass benign malignant
ovarian cancer early stage difficult diagnose symptom nonspecific little use diagnosis result rarely diagnose spread advance later stage additionally symptom ovarian cancer appear similar irritable bowel syndrome
patient pregnancy possibility level measure diagnosis process
serum neuron-specific lactate dehydrogenase measure young girl adolescent suspect ovarian tumor younger patient likely malignant germ cell
physical examination pelvic examination pelvic ultrasound otherwise essential diagnosis physical examination reveal increase abdominal girth ascite fluid abdominal cavity pelvic examination reveal ovarian abdominal mass adnexal mass significant find indicate ovarian cancer especially fix nodular irregular solid bilateral mass cause malignancy benign cause adnexal mass ovarian follicular cyst endometriosis ectopic pregnancy abscess ovarian torsion cyst cystadenoma diverticular abscess nerve sheath tumor pelvic kidney bladder benign cystic mesothelioma peritoneum peritoneal tuberculosis cyst
ovary felt sign ovarian cancer postmenopausal women
part physical examination suspect ovarian cancer include breast examination digital rectal exam
palpation supraclavicular axillary inguinal lymph node reveal lymphadenopathy indicative metastasis
indicator presence pleural effusion note
ovarian malignancy include list diagnostic possibility limit number laboratory test indicate
complete blood count serum electrolyte test usually obtain ovarian cancer present test show high number platelet people low blood sodium level due chemical signal secret tumor positive test inhibin inhibin b indicate granulosa cell tumor
blood test marker molecule call useful differential diagnosis follow disease show effective method screen ovarian cancer due unacceptable low sensitivity specificity level people uml indicate ovarian cancer elevation ca-125 uml people
level accurate early stage ovarian cancer fully stage ovarian cancer patient normal ca-125 level elevate benign non-cancerous condition endometriosis pregnancy uterine fibroid menstruation ovarian cyst systemic liver disease inflammatory bowel disease pelvic inflammatory disease he4 candidate ovarian cancer test extensively test
tumor marker ovarian cancer include ca72-4 immunosuppressive acidic protein mesothelin acid fibroblast growth factor
use blood test panel help diagnosis ova1 panel include microglobulin transferrin
ova1 people postmenopausal people indicate high risk cancer different set laboratory test use detect sex
high level testosterone dehydroepiandrosterone combine symptom high level inhibin indicative scst type
current research look way consider tumor marker combination indicator disease ie radiology symptom improve diagnostic accuracy
challenge approach disparate prevalence ovarian cancer mean even test high sensitivity specificity lead number false positive result turn lead issue perform surgical procedure cancer found
citation need approache develop ovarian cancer
ct scan prefer assess extent tumor abdominopelvic cavity magnetic resonance image use ct scan useful find cake differentiate fluid solid tumor abdomen especially low malignant potential
detect smaller tumor
sometime chest x-ray use detect metastase chest pleural effusion
test metastatic disease infrequently use barium enema show rectosigmoid colon involve disease
emission tomography bone scan paracentesis limit use fact cause metastase form needle insertion site provide useful result use case pelvic mass ascite present physician suspect ovarian cancer perform endometrial biopsy case abnormal bleed assess possibility breast malignancy endometrial malignancy respectively
ultrasonography first-line image study perform adnexal mass found
characteristics adnexal mass indicate ovarian malignancy usually solid irregular multilocular large typically feature central vessel irregular internal septation definitive characteristics radiographic study
definitively diagnose ovarian cancer surgical procedure inspect abdomen require
open procedure laparotomy incision abdominal wall keyhole surgery laparoscopy
procedure suspicious tissue remove sent microscopic analysis
usually include unilateral salpingo-oophorectomy removal single affect ovary fallopian tube
fluid abdominal cavity analyze cancerous cell
cancer found procedure use determine extent spread form tumor stage risk score
widely recognize method estimate risk malignant ovarian cancer risk malignancy index rmi calculate base initial rmi score generally felt indicate high risk ovarian cancer
rmi calculate
rmi ultrasound score menopausal score level
method use determine ultrasound score menopausal score resultant score refer rmi rmi respectively method use
feature rmi rmi
ultrasound abnormality
cyst solid area ascite intra-abdominal metastase
abnormality abnormality abnormality
none abnormality abnormality
quantity quantity
method quantify risk ovarian cancer risk ovarian cancer algorithm roca observe level time determine increase rapidly warrant ultrasound risk malignancy algorithm use level he4 level calculate risk ovarian cancer effective rmi
iota model use estimate probability adnexal tumor malignant include risk model simple rule risk calculation assessment different neoplasia adnexa model use assess risk malignancy adnexal mass base characteristics risk factor
qcancer algorithm use predict likelihood ovarian cancer risk factor pathology ovarian cancer women area represent incidence color represent five-year relative survival rate
ovarian cancer classify microscopic appearance structure histology histopathology
histology dictate aspect clinical treatment management prognosis
gross pathology ovarian cancer similar regardless type solid cystic mass seer type ovarian cancer women age percent ovarian cancer women age percent ovarian cancer women age
subdivision histology 897 surface tumor adenocarcinoma borderline adenocarcinoma underestimate short data collection interval otherwise specify tumor ovarian tumor adenocarcinoma otherwise specify sex tumour carcinoma specify tumor cell tumor specify 851 otherwise specify squamous cell carcinoma brenner tumor specify 717
ovarian cancer histologically genetically divide type type
type cancer low histological grade include mucinous clear-cel carcinoma
type cancer higher histological grade include carcinoma epithelial carcinoma pathological specimen ovarian carcinoma
surface tumour known ovarian epithelial carcinoma common type ovarian cancer represent approximately ovarian cancer
include tumour tumor mucinous
common tumor malignant brenner tumor transitional cell carcinoma ovary
ovarian cancer develop epithelium layer cell cover ovary carcinoma
people epithelial ovarian carcinoma serous carcinoma proportion estimate high low-grade carcinoma aggressive high-grade serous carcinoma typically respond well chemotherapy hormonal treatment carcinoma thought begin fallopian tube adenocarcinoma psammoma body
serous adenocarcinoma resemble fallopian tube epithelium high-grade serous adenocarcinoma show nuclear atypia
time carcinoma bilateral case spread ovary time diagnosis
diameter cm carcinoma
ovarian carcinoma rare aggressive main subtype pulmonary
typically fatal year diagnosis
small cell ovarian carcinoma overwhelmingly affect cause high blood calcium level affect ovary
pulmonary small cell ovarian cancer usually affect ovary older women look carcinoma lung primary peritoneal carcinoma main article primary peritoneal carcinoma
primary peritoneal carcinoma develop peritoneum membrane cover abdominal cavity embryonic origin ovary
discuss classify ovarian cancer affect ovary develop even ovary remove appear similar clear-cel carcinoma
ovarian carcinoma typically respond well chemotherapy relate endometriosis represent approximately endometrial cancer
japanese women develop ovarian cancer frequently group women adenocarcinoma cell seen clear cell carcinoma sample
adenocarcinoma histopathologically similar clear cell carcinoma clear cell hobnail cell
represent approximately epithelial ovarian cancer associate endometriosis pelvic cavity
typically early-stage therefore curable surgery advance clear-cel adenocarcinoma approximately poor prognosis resistant platinum chemotherapy
adenocarcinoma make approximately epithelial ovarian cancer
typically low-grade endometrioid adenocarcinoma good prognosis
frequently co-occur endometriosis endometrial cancer mix müllerian tumor
mix müllerian make ovarian cancer
epithelial mesenchymal cell visible tend poor prognosis
include adenocarcinoma mucinous adenocarcinoma main article adenocarcinoma
adenocarcinoma make epithelial ovarian cancer
similar intestinal cervical adenocarcinoma actually metastase appendiceal colon cancer
advance mucinous adenocarcinoma poor prognosis generally worse tumor resistant platinum chemotherapy rare main article
peritoney refer collection encapsulate mucous material abdominopelvic cavity rarely cause primary ovarian tumor
commonly associate ovarian metastase intestinal cancer epithelial
cancer cell type determine make epithelial ovarian cancer comparatively poor prognosis examine microscope tumor abnormal cell arrang clump sheet
usually recognizable clump serous cell tumor brenner tumor main article brenner tumor
malignant brenner rare
dense fibrous stroma area transitional epithelium squamous differentiation
classify malignant brenner tumor brenner tumor focy transitional cell carcinoma
transitional cell carcinoma component typically poorly differentiate resemble urinary tract cancer transitional cell carcinoma main article transitional cell carcinoma
transitional cell carcinoma represent ovarian cancer
appear similar bladder carcinoma
prognosis intermediate better epithelial cancer worse malignant brenner sex tumor main article sex tumor
sex tumor granulosa cell tumor benign thecoma sertoli-leydig cell tumor arrhenoblastoma account ovarian cancer
occur frequently women year age occur women age young girl
typically aggressive usually unilateral therefore usually treate surgery alone
sex cord-stromal main ovarian tumor
different cell mesenchyme give rise sex-cord stromal tumor
include fibroblast endocrine cell
symptom sex-cord stromal ovarian tumor differ type ovarian cancer
common sign symptom include ovarian torsion rupture tumor abdominal mass hormonal disruption
children precocious pseudopuberty occur cell produce
tumor cause abnormality menstruation excessive bleed infrequent menstruation menstruation postmenopausal bleed
tumor produce cause occur time endometrial cancer breast cancer
sex-cordstromal present distinct symptom
cell cause excessive hair growth due production testosterone androstenedione cause syndrome rare case
stromal tumor occur cause hormonal imbalance benign fibroma cause ascite hydrothorax germ cell sex tumor common ovarian cancer diagnose women cell tumor
cell common stromal tumor make case divide histologic subtype adult cell develop women juvenile granulosa develop puberty age
develop ovarian follicle population cell surround cell adult cell tumor
adult cell tumor characterize later onset year average
tumor produce high level estrogen cause characteristic symptom endometrial hyperplasia tender enlarge breast postmenopausal bleed secondary amenorrhea
mass tumor cause symptom abdominal pain distension symptom similar ectopic pregnancy tumor bleed rupture juvenile granulosa cell tumor cell tumor
common women age particularly common puberty stromal tumor
stromal tumor typically occur girl puberty women age germ cell tumor main article germ cell
cell tumor ovary develop ovarian germ cell cell tumor account ovarian tumor ovarian cancer germ-cel tumor teratoma benign
tend occur older women germ layer tumor develop squamous cell carcinoma tend occur young women girl make ovarian cancer seen age group include yolk sac sinus choriocarcinoma arise ovary
germ-cel isochromosome arm chromosome delet replace duplicate germ-cel cancer better prognosis subtype sensitive chemotherapy
likely stage diagnosis overal metastasize frequently epithelial ovarian cancer
addition cancer marker use vary tumor type monitor beta-hcg sinus
typically discover become large palpable mass
sex cord cause ovarian torsion hemorrhage children precocious puberty
frequently metastasize nearby lymph node especially pelvic lymph node common symptom germ cell tumor subacute abdominal pain cause tumor bleed stretch ovarian capsule
tumor rupture cause significant bleed torse ovary cause acute abdominal pain occur tumor
secrete hormone change menstrual cycle
cancer discover routine examination cause symptom
germ cell difficult normal menstrual cycle puberty cause pain pelvic symptom young woman even believe symptom pregnancy seek treatment due stigma teen pregnancy
blood test karyotype human chorionic gonadotropin liver function use diagnose germ cell tumor potential dysgenesis
germ cell tumor initially mistaken benign ovarian cyst main article
account ovarian cancer young women likely germ cell tumor metastasize lymph node nodal metastase occur 2530 case tumor mutation kit gene mutation known role gastrointestinal stromal tumor
people karyotype ovary dysgenesis x0 ovary turner syndrome develop unilateral dysgerminoma risk gonadoblastoma ovary case ovary usually remove unilateral dysgerminoma discover avoid risk malignant tumor
gonadoblastoma people swyer turner syndrome become malignant approximately case
general dysgerminoma bilateral time
compose cell differentiate further develop directly germ cell
contain approximately case therefore cause elevate hcg level
gross appearance typically pink tan-color multiple lobe solid
appear identical seminoma close embryonic primordial germ cell large round clear cell
nucley uniform round square prominent nucleoly cytoplasm high level glycogen
prominent histologic feature choriocarcinoma main article
occur primary ovarian tumor develop germ cell usually gestational disease metastasize ovary
primary ovarian choriocarcinoma poor prognosis occur pregnancy
produce high level hcg cause early puberty children irregular heavy menstruation menarche immature solid main article immature teratoma
immature solid teratoma common type ovarian germ cell tumor make 4050 case
characterize presence disorganize tissue arise embryonic germ layer mesoderm endoderm immature undifferentiate stem cell make malignant mature dermoid cyst
different tissue visible gross pathology include bone cartilage hair mucus sebum tissue visible outside appear solid mass lobe cyst
large amount neuroectoderm organize sheet tubule amount neural tissue determine histologic grade
immature teratoma usually affect ovary dermoid cyst usually metastasize peritoneum
cause mature teratoma implant grow abdomen disease call grow teratoma syndrome usually benign continue grow chemotherapy necessitate further surgery
mature immature teratoma form adhesion make likely cause ovarian torsion
specific marker immature teratoma antigen ca-125 afp sometime indicate immature teratoma
stage teratoma make majority case best prognosis patient survive year stage tumor grade treate unilateral surgery
stage tumor make remain quarter case worse prognosis 7388 patient survive year mature cyst main article cyst
mature teratoma dermoid cyst rare consist mostly benign tissue develop menopause
tumor consist disorganize tissue nodule malignant tissue various type
common malignancy squamous cell carcinoma adenocarcinoma carcinoma carcinoid tumor tumor malignant melanoma sarcoma sebaceous tumor ovariy part dermoid cyst
treate surgery adjuvant platinum chemotherapy radiation sac sinus tumor main article sac tumor
sac formerly call sinus make approximately ovarian germ cell malignancy worst prognosis ovarian germ cell
occur menarche case menarche remain case
people yolk sac diagnose stage
typically unilateral metastasis occur peritoneal cavity bloodstream lung
sac grow quickly recur easily easily treatable recure
stage yolk sac highly treatable 5-year disease free survival rate stage tumor treatable survival rate
gross appearance solid friable yellow necrotic hemorrhagic area
contain cyst degenerate rupture
yolk sac characterize presence schiller-duval body pathognomonic yolk sac reticular pattern
sac commonly secrete immunohistochemically stain presence level alpha-fetoprotein blood useful marker recurrence carcinoma main article carcinoma
carcinoma rare tumor type usually found mix tumor develop directly germ cell terminally differentiate rare case develop gonad
develop further variety neoplasm yolk sac tumor teratoma
occur younger people average age diagnosis secrete alpha-fetoprotein case hcg
embryonal carcinoma appear similar embryonic disc made epithelial anaplastic cell disorganize sheet gland-like space papillary structure main article
polyembryoma immature form teratoma rare ovarian tumor histologically characterize embryo-like body structure resemble germ disk yolk sac amniotic sac
giant cell occur squamous cell carcinoma
primary ovarian squamous cell carcinoma rare poor prognosis advance
typically ovarian squamous cell carcinoma cervical metastase area differentiation endometrioid tumor derive mature mix tumor
mix tumor contain element above class tumor histology
class mix tumor minor type make tumor mix carcinoma combination cell type mix ovarian cancer typically serousendometrioid clear mix germ cell make approximately germ cell ovarian cancer combination yolk sac tumor immature teratoma
prognosis treatment vary base component cell type secondary ovarian cancer
ovarian cancer secondary cancer result metastasis primary cancer elsewhere body ovarian cancer due metastase rest primary cancer
citation need common primary cancer breast cancer colon cancer cancer stomach cancer primary gastric cancer metastasize ovary call krukenberg signet ring cell mucinous cell cancer lymphoma metastasize ovary low malignant potential
low malignant potential ovarian call borderline tumor benign malignant feature make approximately ovarian tumor develop earlier epithelial ovarian cancer age
typically extensive invasion tumor area stromal microinvasion 3mm tumor
abnormal feature increase mitosis change cell size nucleus size abnormal nucley cell stratification small projection cell projection
andor characteristics seen histological examination histology make overwhelm majority advance lmp
tumor stage stage stage implant lmp tumor non-invasive
ovarian cancer stage use figo stage system use information obtain surgery include total abdominal hysterectomy midline laparotomy removal usually ovary fallopian tube usually omentum pelvic peritoneal wash assessment lymph node pelvic para-aortic lymph node suspect mucinous biopsy cytopathology ovarian cancer appear confine ovary microscopically even cancer stage completely cancer presume stage observe lymphatic metastase ajcc stage figo stage
ajcc stage system describe extent primary tumor absence presence metastasis nearby lymph node absence presence distant metastasis m common stage diagnosis stage diagnose adenocarcinoma deposit mesentery small bowel stage ovarian cancer stage description cancer completely limit ovary ia involve ovary capsule intact tumor ovarian surface negative wash ib involve ovary capsule intact tumor ovarian surface negative wash ic tumor involve ovary surgical spill capsule rupture tumor ovarian surface positive ascite wash pelvic extension tumor confine pelvis primary peritoneal tumor involve ovary iia tumor found uterus fallopian tube iib tumor elsewhere pelvis cancer found pelvis retroperitoneal lymph node involve ovary metastasis lymph node microscopic extrapelvic metastasis metastasis lymph node metastasis mm diameter metastasis greater mm diameter microscopic metastasis peritoneum regardless lymph node status metastasis peritoneum equal cm diameter regardless lymph node status metastasis liver spleen capsule metastasis peritoneum greater cm diameter regardless lymph node status metastasis liver spleen capsule distant metastasis ie outside peritoneum iva pleural effusion contain cancer cell metastasis distant organ parenchyma spleen liver metastasis inguinal extra-abdominal lymph node
stage ovarian cancer
stage ovarian cancer
stage ovarian cancer
stage ovarian cancer
ajcctnm stage system indicate tumor develop spread lymph node metastasis stage ovarian cancer stage description primary tumor assess evidence limit ovaryovary ovary intact capsule surface tumor negative ascitesperitoneal wash ovary intact capsule surface tumor negative ascitesperitoneal wash ovary rupture capsule capsule surface tumor positive ascitesperitoneal wash ovary pelvis extension implantation expansion uterus fallopian tube negative wash expansion pelvic tissue negative wash expansion pelvic tissue positive ascitesperitoneal wash ovary metastasize pelvis peritoneum liver capsule microscopic metastasis metastasis cm diameter metastasis greater cm diameter regional lymph node metastasis assess metastasis present m distant metastasis metastasis metastasis present liver capsule liver parenchyma confirm pleural effusion
ajcctnm stage correlate figo stage ia t1a ib t1b ic t1c iia t2a iib t2b grade
grade well differentiate cell look similar normal tissue best prognosis
grade tumor call moderately made cell resemble normal tissue
grade worst prognosis cell abnormal refer poorly differentiate
metastasis ovarian cancer common abdomen occur cancer cell burst ovarian capsule able move freely peritoneal cavity
ovarian cancer metastase usually grow surface organ common omentum peritoneal line
cancer cell travel lymphatic system metastasize lymph node connect ovary blood vessel ie lymph node infundibulopelvic ligament broad ligament round ligament
commonly affect group include paraaortic external iliac inguinal lymph node
usually ovarian cancer metastasize liver lung brain kidney recurrent disease differentiate ovarian cancer form cancer screen
simple reliable way test ovarian cancer women sign symptom
screen recommend women average risk evidence support reduction death high rate false positive test lead surgery accompany risk pap test screen ovarian cancer
ovarian cancer usually palpable advance stage screen recommend use measurement level ultrasound palpation women average risk
risk develop ovarian cancer genetic factor reduce
genetic predisposition benefit screen
high risk group benefit earlier detection
ovarian cancer low prevalence even high-risk group women age screen women average risk likely give ambiguous result detect problem require treatment
ambiguous result likely detection treatable problem usual response ambiguous result invasive intervention women average risk potential harm screen indication outweigh potential benefit
purpose screen diagnose ovarian cancer early stage likely treate successfully
screen ultrasound pelvic examination ca-125 level use instead preventive surgery women brca1 mutation
strategy show success prevention
people strong genetic risk ovarian cancer consider surgical removal ovary preventive measure
completion childbear year
reduce chance develop breast cancer ovarian cancer people high risk
women gene mutation usually fallopian tube remove time increase risk fallopian tube cancer
statistics overestimate risk reduction study
people significant family history ovarian cancer refer genetic counselor see test brca mutation beneficial use oral contraceptive absence period menstrual cycle tubal ligation reduce risk association develop ovarian cancer ovarian stimulation infertility treatment
link ovarian cancer
human papillomavirus infection smoke talc identify increase risk develop ovarian cancer management
determine ovarian fallopian tube primary peritoneal cancer present treatment schedul gynecologic physician train treat cancer woman reproductive system
perform surgery give chemotherapy women ovarian cancer
treatment plan develop
treatment usually involve surgery chemotherapy sometime radiotherapy regardless subtype ovarian cancer surgical treatment sufficient malignant tumor confine ovary
addition chemotherapy require aggressive tumor confine ovary
patient advance disease combination surgical reduction combination chemotherapy regimen standard
borderline even follow spread outside ovary manage well surgery chemotherapy seen useful second-look surgery maintenance chemotherapy show provide benefit surgery
surgery standard care decade necessary obtain specimen diagnosis
surgery depend extent nearby invasion tissue cancer diagnose
extent cancer describe assign stage presume type grade cancer
gynecological surgeon remove unilateral oophorectomy ovary bilateral
fallopian tube uterus hysterectomy omentum omentectomy remove
typically organ remove
low-grade unilateral stage-ia cancer involve ovary unrupture fallopian tube remove
especially young people wish preserve fertility
risk microscopic metastase exist stage complet metastase found second surgery remove remain ovary uterus need acid administer surgery reduce need blood transfusion due blood loss surgery
tumor premenopausal woman determine low malignant potential tumor surgery clearly stage cancer affect ovary remove
postmenopausal women low malignant potential hysterectomy bilateral salpingo-oophorectomy prefer option
stage appendix examine remove
particularly important tumor children adolescent ovarian cancer surgeon typically attempt preserve ovary allow completion puberty cancer spread alway possible
dysgerminoma particular tend affect ovary present ovary people low-grade well-differentiate typically treate surgery curative general germ cell treate unilateral surgery cancer widespread fertility factor
advance cancer complete removal option tumor possible remove procedure call surgery
surgery alway successful likely successful women extensive metastase peritoneum iv disease cancer transverse fissure liver diaphragm large area ascite
surgery usually complete debulk associate better outcome women macroscopic evidence disease debulking median survival month oppose month complete surgery remove metastase cell resistant chemotherapy remove clump cell dy remove
allow chemotherapy better reach remain cancer cell likely fast-grow therefore
debulk surgery protocol use chemotherapy give surgery perform chemotherapy finish debulk definitive study complet show approximately equivalent primary debulk surgery term survival show slightly lower morbidity
different surgical procedure employ treat ovarian cancer
stage cancer keyhole surgery use metastase found
advance cancer laparoscopy use debulk metastase require access entire peritoneal cavity
extent cancer procedure include bilateral salpingo-oophorectomy biopsy peritoneum abdominal lymphatic system bowel resection diaphragm strip resection even posterior pelvic exenteration
fully stage ovarian cancer lymphadenectomy include surgery significant survival benefit practice happen particularly important germ cell frequently metastasize nearby lymph node
ovarian cancer recur secondary surgery sometime treatment option
depend easily tumor remove fluid accumulate abdomen overal health helpful people surgery generalist epithelial ovarian cancer secondary surgery effective dysgerminoma immature teratoma
major side effect oophorectomy younger women early menopause cause osteoporosis
surgery hormone replacement therapy consider especially younger women
therapy consist combination estrogen progesterone alone
alone safe hysterectomy uterus present unoppose estrogen dramatically raise risk endometrial cancer therapy surgery change survival rate people ovarian cancer surgery typically hospitalize afterward day spend month recover home surgery outcome best hospital large number ovarian cancer surgery
unclear laparoscopy laparotomy better worse stage ovarian cancer apparent difference total abdominal hysterectomy hysterectomy advance cancer
approximately people surgery advance ovarian cancer die week surgery mortality rate aggressive surgery associate better outcome advance stage ovarian cancer
general standard care ovarian cancer decade variable protocol
use surgery treat residual disease appropriate
case reason perform chemotherapy follow surgery
call chemotherapy common tumor completely remove optimally debulk surgery
show increase survival reduce risk complication surgery
unilateral salpingo-oophorectomy surgery perform additional chemotherapy call adjuvant chemotherapy give chemotherapy use stage cancer typically tumor high histologic grade grade highest substage stage cancer optimally stage surgery use adjuvant chemotherapy tumor completely remove surgery cancer stage extend survival show extend overal survival chemotherapy curative approximately advance ovarian cancer curative malignant germ cell epithelial
chemotherapy ovarian cancer typically consist group platinum-base drug combine
common therapy include cisplatin doxorubicin
typically give combination paclitaxel docetaxel typical combination carboplatin carboplatin superior cisplatin toxic side effect generally allow improve quality life comparison similarly effective three-drug regimen found effective platin alone nonplatin alone effective platin nonplatin combination give intravenously peritoneal cavity intraperitoneal chemotherapy associate longer progression-free survival overal survival cause adverse side effect intravenous chemotherapy mainly use cancer optimally debulk
chemotherapy highly effective ovarian cancer mainly spread peritoneal cavity higher dose drug reach tumor way
cause intravenous iron found effective oral iron supplement reduce need blood transfusion typical cycle treatment involve treatment week repeate week week cycle treatment effective week germ-cel malignancy treate differently ovarian cancer regimen bleomycin cisplatin bep use day chemotherapy administer week cycle germ cell show cause infertility birth defect miscarriage maintenance chemotherapy show effective
people mutation platinum chemotherapy effective germ-cel malignant sex-cordstromal treate chemotherapy tumor typically responsive
ovarian cancer recur consider partially platinum-resistant base time recurrence treate partially platinum-sensitive cancer recure month treatment platinum-resistant cancer interval month
chemotherapy give cancer become symptomatic difference survival seen treate asymptomatic elevate ca-125 symptomatic recurrence
medical citation need
tumor platin drug choice chemotherapy combination cytotoxic agent
include combine liposomal doxorubicin carboplatin-doublet therapy combine paclitaxel increase efficacy case
potential adjuvant therapy platinum-sensitive recurrence olaparib improve survival show improve overal survival parp inhibitor approve fda use ovarian cancer previously treate chemotherapy recurrent germ cell additional cycle chemotherapy first-line treatment tho treate surgery platin
tumor determine platinum-resistant dactinomycin cyclophosphamide combination paclitaxel use second-line therapy
tumor high-efficacy chemotherapy option
regimen high response rate single-drug regimen pegylate liposomal use case use people intestinal blockage
use alone possible regimen combine doxorubicin cisplatin topotecan cyclophosphamide see care
radiation therapy
effectively treate radiation cause infertility phase favor chemotherapy radiation therapy improve survival people tumor
stage cancer radiation therapy use surgery possibility residual disease pelvis abdomen cancer-free
radiotherapy use palliative care advance cancer
typical course radiotherapy ovarian cancer day week week
common side effect radiotherapy include constipation frequent urination therapy
fact ovarian tumor estrogen receptor ovarian cancer rarely responsive hormonal treatment
alone effect cancer tamoxifen rarely effective women borderline malignancy ovarian cancer stromal ovarian cancer receive hormonal therapy
topic current research ovarian cancer
case antibody drug topic active research use treat advance cancer chemotherapy approve use european union follow-up
specific follow-up depend example type stage ovarian cancer treatment presence symptom
usually check-up appointment made month initially follow twice year year epithelial ovarian cancer common test follow-up level
treatment base elevate ca-125 level symptom increase side effect prolongation life implication outcome ca-125 test discuss take recommendation 2014 recurrent cancer present ca-125 level twice normal treate recurrence detect ca-125 improve survival
women tumor follow-up test generally include afp human chorionic gonadotropin
women stromal cancer test hormone testosterone sometime helpful inhibin useful monitor progress tumor along inhibit substance
afp use monitor tumor lactate dehydrogenase isozyme use test recurrence
women ovarian cancer need routine surveillance image monitor cancer new symptom appear tumor marker begin rise image indication discourage unlikely detect recurrence improve survival cost side effect ct image use desire common tumor easily image image use monitor progress treatment care
care focuse relieve symptom increase maintain quality life
type treatment purpose cure cancer make woman comfortable live cancer cure
recommend part treatment plan person advance ovarian cancer patient significant symptom platinum-refractory platinum-resistant case palliative chemotherapy main treatment
care entail treatment symptom complication cancer pain nausea constipation ascite bowel obstruction pleural effusion mucositis
especially cancer advance become incurable treatment symptom become main goal therapy
care entail help decision-make hospice care appropriate prefer place patient end life care
bowel obstruction treate palliative surgery colostomy ileostomy internal bypass medicine surgery show increase survival time surgery result short bowel syndrome fistula re-obstruction possible extent obstruction treatment complication include total parenteral nutrition low-residue diet palliative adequate pain control bowel obstruction treate octreotide palliative surgery option
cancer block ureter relieve nephrostomy ureteric stent
relieve repeate paracentesis placement drain increase comfort effusion treate similar manner repeate thoracentesis placement drain
radiation therapy use part palliative care advance ovarian cancer help shrink cause symptom radiotherapy typically last treatment shorter course therapy radiotherapy use palliation germ cell care
ovarian cancer significant effect quality life psychological health well-be
available help need social support
ovarian cancer survivor report good quality life optimism
report spiritual change help find mean experience
describe loss faith diagnosis ovarian cancer
gone treatment sometime experience social isolation benefit relationship survivor
frustration guilt describe express inability care family
body image change occur due hair loss removal ovary reproductive structure scar
improvement hair grow
sexual issue develop
removal ovary result menopause result painful intercourse vaginal dryness loss sexual desire tire
prognosis better younger survivor impact sexuality substantial
anxiety depression distress present survive ovarian cancer higher rate general population psychosocial problem develop family member
emotional effect include fear death sadness memory problem difficulty concentrate
optimism adopt begine treatment likely develop distress
fear cancer recure difficulty express joy even
treatment woman undergoe likely loss hope express
women cope reduce negative psychosocial effect number strategy
activity spend additional time family friend ignor statistics increase involvement spiritually-base event adaptive relative five-year survival invasive epithelial ovarian cancer stage
ovarian cancer usually relatively poor prognosis
disproportionately deadly lack clear early detection screen test mean case diagnose reach advance stage
ovarian cancer metastasize early development diagnose
tumor readily low-grade
typically tumor cell begin metastasize grow peritoneal cavity women present ovarian cancer stage-iiy cancer spread ovary
ovarian cancer shed cell naturally occure fluid abdominal cavity
cell implant abdominal peritoneal structure uterus urinary bladder bowel line bowel wall omentum form new tumor growth cancer even suspect
five-year survival rate stage ovarian cancer one-year survival rate ten-year survival rate case diagnosis made early disease cancer confine primary site five-year survival rate 927 women advance disease respond initial treatment attain complete remission half women experience recurrence year treatment brain metastasis common stage cancer occur cancer stage
people brain metastase survive median month surgery chemotherapy whole brain radiation therapy improve survival
ovarian cancer survival vary significantly subtype
favorable prognosis
early stage five-year survival rate diagnose stage stage-iiy five-year survival treate chemotherapy incomplete surgical removal two-year survival rate
malignancy favorable prognosis slow-grow metastatic disease survive decade low malignant potential usually bad prognosis invasive tumor implant found peritoneal cavity
complication ovarian cancer include spread cancer organ progressive function loss various organ ascite intestinal obstruction fatal
intestinal obstruction multiple site common proximate cause death intestinal obstruction ovarian cancer true obstruction tumor block intestinal lumen pseudo-obstruction tumor prevent normal peristalsis continuous accumulation ascite treate place drain self-drain factor
number prognostic factor ovarian cancer
positive prognostic factor indicate better chance survival include residual disease surgery stage complete macroscopic resection stage brca2 mutation young age year type low histologic grade early stage co-occurrence endometrial cancer low ca-125 level
conflict evidence brca1 prognostic factor
conversely negative prognostic factor indicate worse chance survival include rupture ovarian capsule surgery older age year type stage high histologic grade clear cell type upper abdominal involvement high ca-125 level presence tumor cell blood elevate cyclooxygenase-2
expression various mrna prognostic ovarian cancer
high level drosha associate improve survival high level hif1a polymerase associate worse survival
cancer positive wt1 carry worse prognosis positive cancer better prognosis survival rate
overal five-year survival rate type ovarian cancer present stage grade stage survival 9095 grade survival low grade intermediate grade high grade
survival rate give different type ovarian cancer american cancer society come national cancer institute base patient diagnose
epithelial ovarian cancer stage five-year survival rate ia ib ic iia iib stromal tumor stage five-year survival rate cell tumor ovary stage five-year survival rate fallopian tube carcinoma stage five-year survival rate low malignant potential stage five-year survival rate rate
ovarian cancer frequently recur treatment
overal 5-year period stage cancer recur
recurrence abdomen recurrence occur advance disease typically occur month initial treatment month survival
treate disease-free interval tend shorten chemoresistance increase recurrence dysgerminoma recur likely recur year diagnosis malignant germ cell recur year time
cell poor prognosis relapse long-term survival rate low malignant potential rarely relapse even surgery treatment choice tumor relapse unilateral surgery previously unaffect ovary typically easily treate surgery
advance tumor take year relapse relapse treate surgery tumor change histological characteristics grown quickly
case significant ascite chemotherapy use
usually indicate rise level progress symptomatic relapse month recurrent sex tumor typically unresponsive treatment aggressive
deadly gynecologic cancer epidemiology death ovarian cancer inhabitant data
number new case occure develop country compare develop country people dy ovarian cancer
increase 113000 number new case year europe approximately women europe lithuania latvia ireland slovakia czech republic highest incidence ovarian cancer portugal cyprus lowest incidence 2008 five-year survival rate
increase survival rate unit state ovarian cancer case diagnose age group
united states estimate new case diagnose women dy ovarian cancer
new diagnose sex-cord stromal tumor
2014 diagnose epithelial ovarian cancer made yearly overal lifetime risk ovarian cancer affect cause death women united states fifth-most common cancer women fourth-most common cause cancer death decrease made ninth-most common cancer women
risk develop specific type ovarian cancer vary
cell sex tumor common epithelial
number new case year women women respectively
young people stromal tumor germ cell total overal ovarian cancer ovarian cancer represent approximately cancer diagnose women united kingdom
common cancer uk women uk incidence rate whole population
unit kingdom approximately 70007100 yearly diagnose 4200 death risk uk similar
ashkenazy jewish women carry mutate brca allele time rest population give higher risk develop ovarian cancer fifth-lead cause cancer-relate death 2008 estimate ovarian cancer fifth-most common cancer women uk women diagnose disease fifth-most common cause cancer death women women dy ethnicity
black women twice risk sex cord-stromal compare non-black women older women
incidence rate women approximately rate ovarian cancer 2008 decrease women 4049 age cohort 5064 age cohort ovarian cancer commonly diagnose menopause age
percent ovarian cancer occur women age women older women likely present advance ovarian cancer pregnancy
germ cell type ovarian cancer likely occur pregnancy
typically diagnose adnexal mass found examination pregnancy tumor seen ultrasound parent level alpha-fetoprotein elevate
cyst dysgerminoma common germ cell pregnancy
cell diagnose pregnancy unlikely metastasize treate surgery case chemotherapy carry risk birth defect
sac immature teratoma grow particularly quickly usually treate chemotherapy even pregnancy optimally debulk treate childbirth animal
report equine mare
report tumor type include cystadenocarcinoma particularly cell tumor research screen
screen hysteroscopy obtain cell sample obtain histological examination develop
similar current pap smear use detect cervical cancer uk collaborative trial ovarian cancer screen test screen technique combine blood test ultrasound study suggest screen procedure effective result publish conclusive evidence screen save live long-term result trial extend publish definitive result end
major problem screen clear progression disease stage noninvasive stage invasive seen possible find cancer reach stage
problem screen method tend find suspicious lesion cancer malignancy assess surgery roca method combine ultrasonography research high-risk women determine viable screen method
investigate normal-risk women show promise wider population study progress determine screen help detect cancer earlier people mutation research
research various prognostic factor ovarian cancer go
recent research show predict lower survival higher stage cancer research investigate benefit surgery recurrent ovarian cancer
active area research immunotherapy show effective trial antibody inhibitor slow growth new blood vessel cancer show promise result especially combination pazopanib slow process blood vessel growth
particularly effective preliminary study stage-iiy cancer cite response rate investigate particularly ovarian cancer pharmacology
inhibitor highly investigate potential treatment 2000 2010 side effect drug particularly well tolerate survival benefit confirm
kinase inhibitor interest tend highly toxic cause
investigate drug selumetinib mapk inhibitor
improve survival correlate mutation found
combine platinum chemotherapy combination positive preliminary result pf equivocal result overal survival
disadvantage treatment side effect profile include high blood pressure proteinuria
drug exacerbate bowel disease lead fistulae bowel perforation
consist antifolate conjugate clinical trial prove beneficial folate receptor overexpress ovarian cancer potential immunotherapy trastuzumab active positive her2neu mutation angiogenesis inhibitor investigate potential ovarian cancer treatment
research combination recurrent ovarian cancer
angiogenesis inhibitor investigate
monoclonal antibody farletuzumab research adjuvant traditional chemotherapy
type immunotherapy involve vaccine
alternative chemotherapy regimen cycle carboplatin current topic research germ cell malignancy
chemotherapy investigation 2000 2010 potential deliver higher dose cytotoxic agent
preliminary trial cisplatin show well tolerate improve survival tolerable regimen research research intraperitoneal chemotherapy agent
specific chemotherapy regimen rare clear-cel cancer investigation combine cisplatin
inhibitor show promise early trial particularly people gene mutation brca protein interact parp pathway
study recurrent ovarian cancer general preliminary study show longer
specifically show greater survival compare doxorubicin treatment investigate
clear predictive responsiveness parp inhibitor parp inhibitor research brca-positive recurrent advance ovarian cancer
parp inhibitor test recurrent ovarian cancer
kinase inhibitor investigational drug class application ovarian cancer
inhibitor receptor tyrosine kinase inhibitor group cediranib show increase progression free survival benefit overal survival investigate preliminary research show combine platin recurrent ovarian cancer increase time second recurrence month increase survival month tyrosine kinase inhibitor use combination paclitaxel carboplatin platinum-sensitive cancer mutation
research potential therapy combination cyclophosphamide people recurrence
deacetylase inhibitor area research
hormone therapy topic current research ovarian cancer particularly value certain medication use treat breast cancer
include tamoxifen
preliminary study show benefit tamoxifen small number people advance ovarian cancer
help slow stop growth receptor positive ovarian cancer
investigate postmenopausal people receptor-positive cancer
research mitigate side effect ovarian cancer treatment ongo
radiation fibrosis formation scar tissue area treate radiation relieve oxygen therapy research complet area
treatment ovarian cancer cause people experience psychiatric difficulty depression
research ongo determine counsel psychotherapy help people ovarian cancer treatment
indication pelvic inflammatory disease associate ovarian cancer especially country
due inflammatory process present pelvic inflammatory disease clinical trial
clinical trial monitor fund governmental organization test treatment option see safe effective
include nih clinical research trial national institute health learn clinical trial national cancer institute search clinical trial national cancer institute national institute health clinical trial conduct canada
